Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients
Outcomes of Thrombolytic Therapy for Acute Ischemic Stroke in Chinese Patients
复制标题
DOI：
--
复制
发表时间：
2010-05
期刊：
影响因子：
8.3
通讯作者：
A-ChingChao;Hung-YiHsu;Chih-PingChung;Chung-HsiangLiu;Chih-HungChen;Michael Mu-HuoTeng;Giia-SheunPeng;Wen-YungSheng;Han HwaHu
中科院分区：
文献类型：
--
作者：
A-ChingChao;Hung-YiHsu;Chih-PingChung;Chung-HsiangLiu;Chih-HungChen;Michael Mu-HuoTeng;Giia-SheunPeng;Wen-YungSheng;Han HwaHu
背景和目的——阿替普酶治疗缺血性卒中的安全性和有效性尚未在中国患者中进行检验。我们在台湾的日常临床实践中评估了阿替普酶治疗急性缺血性中风的安全性和有效性。方法——2004年12月至2008年7月在台湾进行了一项前瞻性、多中心、观察性研究。招募了符合条件的接受阿替普酶治疗的患者（241名）并分为2组：标准剂量组（0.90±0.02 mg/kg，n=125）和较低剂量组（0.72±0.07 mg/kg，n=116）。主要结局指标是安全性：有症状的脑出血和 3 个月内死亡。次要结果指标是 3 个月后的疗效（改良 Rankin 量表 0 至 2）。结果——根据美国国家神经疾病和中风研究所、欧洲急性中风合作研究以及中风监测研究中溶栓安全实施的定义，标准剂量组的症状性脑出血发生率较高（10.4% 与 5.2%、8.0% 与 2.6%...
Background and Purpose— The safety and efficacy of alteplase for ischemic stroke has not been examined in Chinese patients. We assessed the safety and efficacy of alteplase for acute ischemic stroke in daily clinical practice in Taiwan. Methods— A prospective, multicenter, observational study was conducted in Taiwan from December 2004 to July 2008. Eligible patients (241) receiving alteplase were recruited and divided into 2 groups: standard dose (0.90±0.02 mg/kg, n=125) and lower dose (0.72±0.07 mg/kg, n=116). Primary outcome measures were safety: symptomatic intracerebral hemorrhage and death within 3 months. The secondary outcome measure was efficacy a modified Rankin scale of 0 to 2 after 3 months. Results— The standard-dose group had higher rates of symptomatic intracerebral hemorrhage using National Institute of Neurological Diseases and Stroke, European Cooperative Acute Stroke Study, and Safe Implementation of Thrombolysis in Stroke-Monitoring Study definitions (10.4% versus 5.2%, 8.0% versus 2.6%...